Related Experiment Videos
Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): Methods and Design
1AFASAK 2 Study Center, The Copenhagen General Practitioners' Laboratory, Pilestraede 65, DK-1112 Copenhagen K, Denmark.
Insights
This study compares four antithrombotic strategies for atrial fibrillation patients, aiming to find an effective, safe, and convenient stroke prevention method. Results will guide optimal antithrombotic therapy choices.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Anticoagulant therapy is proven effective for stroke prevention in nonvalvular atrial fibrillation (AF).
- The role of aspirin in AF stroke prevention requires further clarification.
- Conventional anticoagulation poses inconvenience and bleeding risks for primary prevention.
Purpose of the Study:
- To evaluate four antithrombotic regimens for primary stroke prevention in AF patients.
- To determine the most effective, safe, and convenient antithrombotic strategy.
- To compare fixed-dose warfarin, warfarin plus aspirin, aspirin alone, and conventional warfarin therapy.
Main Methods:
- The Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulant Therapy Study (AFASAK 2) is a randomized, single-center primary prevention trial.
- Four treatment arms: fixed-dose warfarin, warfarin + aspirin, aspirin alone, conventional warfarin (INR 2.0-3.0).
- Primary endpoint: stroke or thromboembolic events; secondary endpoints include TIA, MI, and death. Intention-to-treat analysis and bleeding complications are assessed.
Main Results:
- This paper presents the study design and methods; results are pending.
- The study aims to identify an antithrombotic therapy that balances efficacy, safety, ease of administration, and cost-effectiveness.
- Bleeding complication rates will be evaluated alongside efficacy outcomes.
Conclusions:
- The AFASAK 2 study is designed to provide crucial data on optimal antithrombotic strategies for nonvalvular atrial fibrillation.
- Findings will inform clinical practice regarding stroke prevention in AF patients.
- The study seeks to establish a superior antithrombotic regimen balancing efficacy and safety.
Abstract:
Background: Seven randomized trials have demonstrated that anticoagulant therapy is effective for primary and secondary prevention of stroke and other thromboembolic events in patients with chronic nonvalvular atrial fibrillation. The effect of aspirin is still not clarified. Conventional anticoagulant therapy is inconvenient as a primary preventive therapy as it requires frequent blood tests and implies a risk of bleeding complications. Purpose and methods: The Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulant Therapy Study (The AFASAK 2 study) is a randomized, one center, primary prevention trial. Its purpose is to investigate the effect of four antithrombotic regimens in patients with atrial fibrillation (1) fixed dose warfarin 1.25 mg per day, (2) a combination of warfarin 1.25 mg per day and aspirin 300 mg per day, (3) aspirin 300 mg per day, and (4) conventional warfarin therapy (INR 2.0-3.0). The primary endpoint is a stroke or a thromboembolic event in viscera or extremities. Secondary endpoints are transient ischemic attack, myocardial infarction, or death. The study will evaluate outcome events on intention-to-treat principles. The rate of bleeding complications is evaluated. The aim is to obtain an antithrombotic therapy for patients with nonvalvular atrial fibrillation that is effective, safe, easy to administer, and inexpensive. The methods and design of the study are presented in this paper.